Compare MC & BLTE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MC | BLTE |
|---|---|---|
| Founded | 2007 | 2018 |
| Country | United States | United States |
| Employees | 1416 | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 6.0B |
| IPO Year | 2014 | 2021 |
| Metric | MC | BLTE |
|---|---|---|
| Price | $68.26 | $151.61 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 7 |
| Target Price | $72.88 | ★ $198.00 |
| AVG Volume (30 Days) | ★ 875.8K | 147.0K |
| Earning Date | 04-29-2026 | 05-08-2026 |
| Dividend Yield | ★ 3.88% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.75 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $18.28 | N/A |
| Revenue Next Year | $17.22 | $492.11 |
| P/E Ratio | $91.51 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $51.06 | $62.18 |
| 52 Week High | $78.22 | $200.00 |
| Indicator | MC | BLTE |
|---|---|---|
| Relative Strength Index (RSI) | 53.64 | 44.35 |
| Support Level | $68.19 | $146.94 |
| Resistance Level | $71.29 | $161.17 |
| Average True Range (ATR) | 2.39 | 7.15 |
| MACD | 0.11 | -1.67 |
| Stochastic Oscillator | 74.96 | 4.70 |
Moelis & Co is an independent investment bank that provides strategic and financial advice to a diverse client base, including corporations, financial sponsors, governments, and sovereign wealth funds. The company assists its clients in achieving their strategic goals by offering comprehensive, globally integrated financial advisory services across all industry sectors. It also advises clients on their critical decisions, including mergers and acquisitions, recapitalizations and restructurings, capital markets transactions, and other corporate finance matters. It generates revenue from advisory transactions. The firm derives a majority of its revenue from the United States, followed by Europe and the rest of the World.
Belite Bio Inc is a clinical stage biopharmaceutical drug development company focused on advancing novel therapeutics targeting degenerative retinal diseases which have unmet medical need such as Geographic Atrophy (GA), the late atrophic (dry) form of age-related macular degeneration (AMD), and Stargardt disease type 1 (STGD1). In addition to its product candidate (tinlarebant) which is intended for the treatment of GA and STGD1, its drug development pipeline also includes a small molecule, orally administered compound, LBS-009, which is intended for the treatment of metabolic diseases such as non-alcoholic fatty liver disease (NAFLD), nonalcoholic steatohepatitis (NASH), type 2 diabetes (T2D), and gout.